Zastosowanie kliniczne świeżo mrożonego osocza w szpitalu referencyjnym w Indiach by Raturi, Manish et al.
77www.jtm.viamedica.pl
ORIGINAL ARTICLE
Journal of Transfusion Medicine 
2017, tom 10, nr 3, 77–83 
Copyright © 2017 Via Medica
ISSN 1689–6017
Address for correspondence: Dr. Shamee Shastry, MD Professor & Head, Department of Immunohematology & Blood Transfusion,  
Kasturba Medical College, Manipal University, Manipal- 576104, Karnataka, Mobile: +91-9743489837, Phone: +91-820-2922448,  
e-mail: shamee.girish@manipal.edu
Clinical Use of Fresh Frozen Plasma in a Tertiary 
Care Hospital from India 
Zastosowanie kliniczne świeżo mrożonego osocza w szpitalu 
referencyjnym w Indiach
Manish Raturi, Shamee Shastry, Mohandoss Murugesan, Poornima B Baliga
Department of Immunohematology & Blood Transfusion, Kasturba Medical College, Manipal University, 
Manipal-576104, Karnataka
Abstract
Background. Increased utilization of fresh frozen plasma (FFP) over the last decade has 
caused a rising trend in its unjustified usage exposing recipients to both infectious and non-
-infectious hazards. The aim of the study was to observe the pattern of clinical use of plasma 
at a tertiary care hospital from India. 
Material and methods. Prospective analysis of all the requests raised for plasma was carried 
out. Indicators namely homogeneity of the requisition forms, patient demographics, indications 
for transfusion, dosage, pre-transfusion coagulation parameters and adverse events were 
noted. Appropriateness was defined based on compliance to both national and international 
standards. Data was analyzed using SPSS version 20 (IBM, USA). 
Results. Total nine hundred ninety eight patients (Males: 66%) received 4991 units of 
plasma at an average of two episodes per patient. Majority were adults 83.6% (n = 835). 
Primary users were internal medicine (32%) and plastic surgery (17%) respectively. Most 
common indication was bleeding with coagulopathy seen in 41% (411/998) patients. Ave-
rage plasma volume administered was 456.2 ± 287.4 (17 to 2800) mL per episode. Pre-
-transfusions INR value was available in only 63.2% (n = 1317) episodes. Overall, 56% (n 
= 1169) episodes were deemed appropriate. Total 0.28% plasma related adverse reactions 
were seen and reported to the national hemovigilance database. Mortality in the study group 
was 7.2%. 
Conclusion. Existing transfusion practices for plasma use were moderately compliant with 
the standards. Commonest indications for inappropriate FFP use were for low protein states 
and prophylaxis without any evidence of bleeding.
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Streszczenie
Wstęp. W ciągu ostatniej dekady znacznie zwiększyło się zużycie świeżo mrożonego osocza 
(fresh frozen plasma, FFP), co spowodowało rosnącą tendencję do nieuzasadnionego stosowa-
nia FFP, a tym samym narażenie pacjentów na ryzyko związane z zakażeniami i niezakaźnymi 
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powikłaniami. Badanie przeprowadzono w celu zaobserwowania, w  jaki sposób stosuje się 
FFP w referencyjnym szpitalu w Indiach. 
Materiał i metody. Przeanalizowano w sposób prospektywny wszystkie przypadki zamówień 
osocza. Stosowano jednorodne formularze zamówienia i  odnotowano dane demograficzne 
chorych, wskazania do transfuzji, dawkę, parametry krzepliwości krwi przed transfuzją oraz 
zdarzenia niepożądane. Prawidłowe stosowanie definiowano jako zgodność z krajowymi i mię-
dzynarodowymi standardami. Do analizy danych użyto oprogramowania SPSS, wersja 20 
(IBM, Stany Zjednoczone). 
Wyniki. Ogółem 998 chorym (66% mężczyzn) podano 4991 jednostek osocza, a średnia licz-
ba transfuzji na pacjenta wynosiła 2. Większość stanowiły osoby dorosłe (83.6%; n = 835). 
Największą grupę stanowili pacjenci internistyczni (32%) i osoby poddające się zabiegom z za-
kresu chirurgii plastycznej (17%). Najczęstszym wskazaniem było krwawienie z koagulopatią 
obserwowane u  41% (411/998) chorych. Średnia objętość podanego osocza wynosiła 456,2 
± 287,4 (17 do 2800) ml na transfuzję. Wartość INR przed transfuzją była dostępna tylko 
w 63,2% (n = 1317) epizodów. Ogółem, 56% (n = 1169) epizodów uznano za prawidłowe. 
W 0,28% przypadków zaobserwowano działania niepożądane i zgłoszono je do krajowej bazy 
nadzoru hematologicznego. Odnotowano 72 przypadki zgonów (7,2% chorych). 
Wnioski. Stosowana praktyka dotycząca transfuzji osocza była umiarkowanie zgodna ze stan-
dardami. Najczęściej stwierdzanymi nieprawidłowościami było stosowanie FFP w przypadku 
niedoborów białkowych i w ramach profilaktyki przy braku jakichkolwiek oznak krwawienia.
Słowa kluczowe: świeżo mrożone osocze, prawidłowe stosowanie,  
zastosowanie kliniczne, wytyczne
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Introduction
Blood components therapy has profoundly im-
pacted the bank inventory as well as patient safety 
over the last two decades. Globally a rising trend 
in the clinical usage of fresh frozen plasma (FFP) 
has been witnessed. However, multiple loop-holes 
exist in its ordering and optimal utilization in com-
pliance to the existing national and international 
standards. Furthermore, FFP carries a potential 
of causing both infectious and non-infectious 
harm to the recipient. Hence the use of FFP is not 
only without potential danger it should be rather 
administered only when clearly indicated [1]. In 
addition, inappropriate usage continues to grow 
invariably from one institution to another ranging 
anywhere from 21.3% to 83% [2]. Surplus interest 
has therefore been shown worldwide, to streamline 
the transfusion practices by means of ensuring 
scientific as well as cost-effective use of plasma. 
Being a 2032 bedded multi-specialty tertiary care 
center and considering the increased demand of 
this selective blood component, we decided to do 
a prospective analysis on the pattern of its ordering, 
dose requested and the compliance of its clinical 
use based on both national [Directorate General 
of Health Services (DGHS)] and international gu-
idelines such as British Committee for Standards 
in Hematology (BCSH) [3, 4]. The primary aim of 
this study was to observe the pattern of clinical 
use of plasma and optimize the existing transfusion 
practices at our center.
Material and methods
It was designed as a prospective study from 
December 2012 to November 2013, where clini-
cians requested for plasma for various reasons. 
A written informed consent was obtained from the 
recipients prior to any transfusion in accordance 
with the hospital transfusion policy. As per the 
institutional policy an approval by the ethical com-
mittee was obtained prior to the commencement 
of the study. It was conducted in accordance with 
the principles of good clinical practices.
Study methodology
The study timeline included the following 
phases: 
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Phase I: It included ten month period (from De-
cember 2012 to September 2013) for prospective 
monitoring of all the transfusion requests of FFP. 
The study was further divided into steps such 
as defining indicators to design a  study crite-
ria-based Proforma, patient demographics (age, 
gender, service and body weight), monitoring of 
the transfusion requisition forms and identifying 
appropriateness of indication and dosage pattern 
to the established guidelines. The complete de-
tails regarding FFP requisitions were collected 
and entered in the Proforma. Data was captured 
simultaneously during every transfusion episode 
(An episode was defined as each time we issued 
one or more therapeutic doses of FFP to a patient).
Phase II: It included two month period (from 
October to November 2013) for final analysis and 
interpretation of the data. 
Defining Study Criteria
Completeness of compilation of requisition 
forms
It was evaluated as the percentage of entry in 
ten areas [patients’ name, age & gender, blood group, 
location, pre-transfusion coagulation parameters, 
provisional diagnosis, history of previous transfusion 
and or any adverse reaction, type of request (urgent 
or planned), type and number of blood component as 
well as requesting doctor’s signature] on the requisi-
tion forms. This was captured in the study Proforma. 
The requests were defined as “excellent” (if greater 
than 70%); “good” (50% and 70%) and “poor”(less 
than 50%) based on the percentage of the areas filled.
Indications for transfusion and dosage
Appropriateness was defined based on compliance 
to both national and international standards. The indi-
cations and dosage of FFP (10–15 mL per kg bodywei-
ght) as ordered on the requisition forms were noted.
Pre & Post-transfusion coagulation  
parameters
Pre-transfusion coagulation parameters like 
prothrombin time (PT), International normalized 
ratio (INR), partial thromboplastin time (PTT) 
and platelet count within 12 hours preceding the 
request and similar parameters performed within 
24 hours after transfusion were considered for 
defining appropriateness.
Adverse reactions
Any adverse transfusion reactions due to FFP 
administration were noted.
Morbidity and mortality
Midterm morbidity and mortality in the treated 
population was obtained from the medical and/or 
nurses clinical records of the patients.
Inclusion & exclusion Criteria
All the hospitalized patients who received FFP 
transfusions were included in the study. However, 
the requests which came to the department for 
plasma exchange procedures were excluded from 
the study because of the lack of supportive guide-
lines to judge the appropriateness of same in such 
situations.
Statistical analysis
SPSS software version 20 (IBM Inc., Armonk, 
NY, USA) was used for data analysis. Simple 
descriptive statistics were expressed as mean 
± standard deviation and quantitative data was 
expressed as percentage. The c2 test was used to 
compare the completeness and appropriateness 
of requests arriving from different specialties; 
p value less than 0.05 was considered as statisti-
cally significant. The two-tailed t-test was used to 
compare paired data such as pre and post transfu-
sion coagulation test values.
Results
Patient demographics
Total nine hundred ninety eight patients (Ma-
les: 66%) received 4991 units of plasma (200 ± 20) 
mL at an average of two episodes per patient. On 
age-wise distribution majority were adults (82%). 
Median weight (inter-quartile range) amongst the 
infants was 2.78 (2.1–3.1), in adolescent 16 (10–29) 
and adults 57 (51.5–61) kg respectively. Blood 
group-wise majority patients were of O group. 
Major users of plasma were internal medicine 
(32%) against plastic surgery (17%). Highest use 
was made in operation theatres (42%) followed by 
intensive care units [ICU] (30%). The commonest 
diagnosis of patients who were administered plas-
ma was liver disease (25.1%) followed by 14.5% 
disseminated intravascular coagulation [DIC] 
(Table 1).
Completeness of the compilation  
of requisition forms
Total two thousand eighty two (2082) requisi-
tion forms were received. They were analyzed for 
homogeneity of completeness. Among them 50% 
[n = 1040/2082] forms were defined as good aga-
inst 3% [n = 62/2082] poorly filled. Pre-coagulation 
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Table 1. Diagnosis-wise distribution of Fresh Frozen Plasma usage in patients
Tabela 1. Rozkład częstości stosowania świeżo mrożonego osocza w zależności od rozpoznania
Diagnosis No. of patients [%] No. of requisition forms
Liver disease 251 (25.1%) 541
*DIC with sepsis 145 (14.5%) 259
Cardiac Surgery 119 (11.9%]) 159
Malignancies 113 (11.3%) 187
Trauma 100 (10.0%) 174
Hypovolemia in Burns 71 (7.1%) 356
Infectious diseases 64 (6.4%) 135
Peri-operatively  
[surgical cases]
46 (4.6%) 74
Poisoning & others 27 (2.7%) 56
Obstetric complications 20 (2.0%) 29
Renal disease 20 (2.0%) 44
#TTP/HUS 11 (1.1%) 36
Factor deficiency 11 (1.1%) 32
Total 998 (100%) 2082
*DIC — disseminated intravascular coagulation; #TTP — thrombotic thrombocytopenic purpura; HUS — hemolytic uremic syndrome
parameters were entered in 71% forms against 
previous transfusion and adverse reactions filled 
in only 13% forms (Fig. 1).
Bleeding sites & invasive procedures
Commonest bleeding sites were upper ga-
strointestinal (32%) followed by mucocutaneous 
(17%). Bleeding of knee joint was present in 60% 
of hemophilia patients. Total 37% (n = 372/998) 
underwent various surgical and/or invasive pro-
cedures. Cardiac & other vascular surgeries were 
performed in 27% (n = 100/372) patients. Prop-
hylactic transfusions were given prior to wound 
debridement, central venous catheterizations and 
liver biopsies in 16% (61/372), 14% (53/372) and 
7% (27/3720 respectively.
Indications and dosage of plasma 
administration
The patients enrolled in the study were diag-
nosed with multiple disorders (Table 1). Most 
common indication was bleeding with coagulopathy 
41% (n = 411) against 17.5% (n = 175) patients 
having hypoalbuminemia/hypovolemia. The median 
dose (Q1-Q3) of FFP administered was 10.1 (5.8 
to 13.4) mL/kg ranging from 0.11 to 48.5 mL per 
episode. Higher dose of plasma was administered 
for the reversal of anticoagulant (11.8 mL) against 
Figure 1. Degree of homogeneity of information on the blood requisition forms
81www.jtm.viamedica.pl
Manish Raturi et al., Clinical Use of Fresh Frozen Plasma in a Tertiary Care Hospital from India
Table 2. Mean dose & changes in INR per episode of transfusion indications along-with appropriateness
Tabela 2. Średnie dawki, średnie zmiany wartości wskaźnika INR na transfuzję osocza i prawidłowość stosowania 
w poszczególnych wskazaniach
Indications No. of patients 
(Mean no. of episo-
des ± S.D)
Mean dose  
mL/kg (± S.D)
Mean change in 
INR per episode 
of plasma (± S.D)
*Appropriate-
ness 
Coagulopathy with
• bleeding
• no bleeding
• invasive procedure
411 (1.98 ± 1.81)
150 (2.17 ± 1.94)
126 (1.62 ± 1.94)
10.9 (± 6.26)
10.5 (± 4.95)
10.6 (± 4.78)
0.41 (± 0.99)
0.35 (± 0.67)
0.22 (± 0.68)
Yes
No
Yes
Prophylactic (Without bleeding and/or 
coagulopathy) 127 (1.46 ± 1.95) 8.17 (± 7.75) –0.01 (± 0.13)
 
No
Low protein state and/or Hypovolemia 175 (3.05 ± 1.94) 10.3 (± 7.74) #N.A. No
Reversal of anticoagulants
• With bleeding
• Without bleeding
    4 (1.50 ± 1.77)
    5 (2.33 ± 1.99)
11.8 (± 4.60)
11.1 (± 3.30)
–0.26 (± 0.68)
–0.15 (± 0.73)
Yes
No
*Based on Director General of Health Services [DGHS] and British Committee for Standards in Hematology [BCSH] guidelines; #N.A. Not Available
coagulopathy with bleeding (10.9 mL) (p < 0.001) 
(Table 2). Further the given dose was higher (10.93 
mL in patients with INR > 3) against patients ha-
ving INR < 1.5 (9.95 mL). There was statistically 
significant correlation between the pre-transfusion 
INR and the dose of plasma used (p = 0.027). In six 
percent (n = 122) of the episodes the exact weight 
of the patients could not be assessed, we therefore, 
did not include such cases for the assessment of 
the appropriateness of the dosage. Total 51% (n = 
1002/1960) episodes were given an appropriate dose 
ranging from 10 to 20 mLkg-1 against 45% (n = 888) 
and 4% (n = 70) episodes of under (< 10 ml kg-1) and 
over dosages (> 20 ml kg-1) respectively (Fig. 2). 
Pre and post-coagulation screening tests
PT/INR value within 12 hours preceding FFP 
transfusions was available in 63% of episodes. 
The average values were available (Mean value = 
36.4/2.64) and varied widely. Post-transfusion PT/ 
/INR was available in only 56% of episodes (Mean va-
lue = 27.8/2.08). There was statistically significant 
change in PT/INR after transfusions (p < 0.001). 
Paired-t test was applied to compare means of both 
pre and post coagulation parameters which showed 
statistical significant change (p < 0.001).
Overall appropriateness based upon 
guidelines
Total 56% (n = 1169/2082) episodes of plasma 
indications, 51% episodes of dosage and 63% availa-
bility of PT/INR were deemed appropriate (Table 2). 
Figure 2. Dosage of Plasma administered to patients 
according to body weight
Overall 56% episodes of plasma transfusions were 
in compliance to the guidelines. 
Adverse events & mortality
Overall of 0.28% (n = 14/4991) of plasma units 
transfused were related with adverse reactions. 
Most were mild allergic (pruritus and urticarial) 
against one case of transfusion related acute lung 
injury (TRALI). Death was seen in 7.2% (n = 
= 72/998) patients primarily associated to massive 
bleed and DIC following trauma.
Discussion
Several guidelines are published and available 
as benchmarks for the optimal use of plasma in 
clinical settings. These recommendations may be 
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adopted or modified according to clinical needs and 
constraints of local institutional policies. Interna-
tional guidelines such as The College of American 
Pathologists (CAP), the British Committee for 
Standards in Hematology (BCSH) and national 
guidelines such as Directorate General of Health 
Services (DGHS) from the ministry of Health and 
Family Welfare, Government of India are among 
few to highlight the same. Interventions to change 
transfusion practices go hand in hand with monito-
ring of the same since both are considered as the 
two sides of a coin [5]. The primary motivation of 
doing this study was to observe the existing trans-
fusion practices for FFP use in clinical settings. 
In addition examining the dose and indication for 
transfusion also becomes an important aspect to 
look at [6]. Segal and Dzik have suggested that 
the inappropriate plasma orders occur because 
of three assumptions mainly that the elevation 
of INR might predict the bleeding in setting of an 
invasive procedure, prophylactic usage of plasma 
will correct the prolonged clotting time results 
and finally with its use fewer bleeding events will 
occur [7]. Right at the beginning of our study we 
believed that a well-structured blood requisition 
form would facilitate us to collect data in a more 
systematic manner. The degree of completeness 
of these forms was considered as an important 
indicator during the data collection phase. The 
overall compilation was found “good” in 50% of 
forms. Literature supports that lack of homogene-
ity of the forms goes on to contribute significantly 
to the inappropriate transfusion practices. Hui et 
al. have shown that changes in blood requisition 
form have a considerable effect on the percentage 
of appropriateness itself [8].
The coagulation screening tests were not or-
dered in burn patients since that was considered 
irrelevant for their management. Other groups of 
patients where plasma transfusions were judged 
out-of-specifications (OOS) were prophylactic 
transfusions (during invasive procedures without 
any evidence of coagulopathy and/or bleeding). Stu-
dies show approximately 30 to 50% of FFP trans-
fusions are prophylactic with or without planned 
surgeries [9]. This indeed constitutes a significant 
grey area demanding scientific evidence since 
there is minimal to no evidence to show benefit 
of any such prophylactic plasma administrations. 
Using the recommended dose criteria, only 51% 
(1002/1960) of episodes depicted an appropriate 
plasma request. A pilot study conducted at Umbria, 
Italy showed dosage appropriateness to be 62.7% 
[10]. Similar study calculated appropriateness ba-
sed upon indications as 55.6% which is comparable 
to our results.
Our study showed generalized and widespread 
irrational usage of plasma across various specia-
lities as a  result of which several patients were 
inadvertently given plasma even when they did 
not require any. We believe that in an organized 
system of clinical expertise along with alert group 
of transfusion medicine residents and technicians, 
it is possible to achieve high rates of appropriate-
ness for transfusion practices. This often requires 
guiding the decision of clinicians.
Allergic (urticarial) transfusion reactions are 
quite commonly reported to be approximately 1% 
to 3% of all blood transfusions [11]. In our study 
0.28% (n = 14/4991) units of plasma transfusion 
related adverse reactions were reported. Majority 
were associated with cutaneous manifestations like 
urticarial rash, pruritus and flushing barring one 
patient who had symptoms suggestive of TRALI. 
We further observed that the transfusion reactions 
as reported by ward nurses were meticulous and 
prompt. All these adverse events were entered in 
the national hemovigilance software in accordance 
with our department protocol.
The present observational study helped us 
to evaluate the existing transfusion practices by 
taking a snapshot of ‘what is happening and how 
it is happening’. The current plasma usage at our 
centre is moderately compliant with the published 
guidelines. Commonest indications observed for 
inappropriate use were low protein states and 
prophylactic use without any evidence of bleeding.
Acknowledgement
The authors gratefully acknowledge all the 
co-operation extended by the technical staff of our 
department.
References
1. Serious Hazards of Transfusion. Annual Report; 2014. Available 
from: http://www.shotuk.org. [Last accessed on 2017 June. ; 01.
2. Chng WJ, Tan MK, Kuperan P. An audit of fresh frozen plasma 
usage in an acute general hospital in Singapore. Singapore Med J. 
2003; 44(11): 574–578, indexed in Pubmed: 15007497.
3. Saran RK. Blood Transfusion Safety and Regulatory Requirements. 
In: Transfusion medicine Technical Manual, 2nd Ed. New Delhi: 
DGHS, Ministry of Health and Family Welfare; 2003. p : 219–20.
4. O’Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Bri-
tish Committee for Standards in Haematology, Blood Transfu-
sion Task Force. Guidelines for the use of fresh-frozen plas-
ma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004; 
126(1): 11–28, doi: 10.1111/j.1365-2141.2004.04972.x, indexed 
in Pubmed: 15198728.
83www.jtm.viamedica.pl
Manish Raturi et al., Clinical Use of Fresh Frozen Plasma in a Tertiary Care Hospital from India
5. Tinmouth A. Reducing the amount of blood transfused by 
changing clinicians’ transfusion practices. Transfusion. 2007; 
47(2 Suppl): 132S–136S; discussion 155S, doi: 10.1111/j.1537-
-2995.2007.01369.x, indexed in Pubmed: 17651336.
6. Tinmouth A, Stanworth S. Aroaches to Blood Utilization Auditing. In: 
Technical Manual, AABB. 17th ed Bethesda, Maryland; 2011 p. : 763–78.
7. Segal JB, Dzik WH. Transfusion Medicine/Hemostasis Clinical 
Trials Network. Paucity of studies to support that abnormal co-
agulation test results predict bleeding in the setting of invasive 
procedures: an evidence-based review. Transfusion. 2005; 45(9): 
1413–1425, doi: 10.1111/j.1537-2995.2005.00546.x, indexed in 
Pubmed: 16131373.
8. Hui CH, Williams I, Davis K. Clinical audit of the use of fresh-
-frozen plasma and platelets in a tertiary teaching hospital and 
the impact of a new transfusion request form. Intern Med J. 2005; 
35(5): 283–288, doi: 10.1111/j.1445-5994.2005.00803.x, indexed 
in Pubmed: 15845110.
9. Stanworth SJ, Grant-Casey J, Lowe D, et al. The use of fresh- 
-frozen plasma in England: high levels of inappropriate use 
in adults and children. Transfusion. 2011; 51(1): 62–70, doi: 
10.1111/j.1537-2995.2010.02798.x, indexed in Pubmed: 
20804532.
10. Iorio A, Basileo M, Marchesini E, et al. Audit of the clinical use 
of fresh-frozen plasma in Umbria: study design and results of 
the pilot phase. Blood Transfus. 2008; 6(4): 211–219, indexed in 
Pubmed: 19112736.
11. Domen RE, Hoeltge GA. Allergic transfusion reactions: an eva-
luation of 273 consecutive reactions. Arch Pathol Lab Med. 2003; 
127(3): 316–320, doi: 10.1043/0003-9985(2003)127<0316:ATR>
2.0.CO;2, indexed in Pubmed: 12653575.
